Literature DB >> 29116637

Epidemiology of Drug-Resistant Tuberculosis.

Anna S Dean1, Helen Cox2, Matteo Zignol3.   

Abstract

As we move into the era of the Sustainable Development Goals (SDGs), the World Health Organization (WHO) has developed the End TB strategy 2016-2035 with a goal to end the global epidemic of tuberculosis (TB) by 2035. Achieving the targets laid out in the Strategy will require strengthening of the whole TB diagnosis and treatment cascade, including improved case detection, the establishment of universal drug susceptibility testing and rapid treatment initiation. An estimated 3.9% of new TB cases and 21% of previously treated cases had rifampicin-resistant (RR) or multidrug-resistant (MDR) TB in 2015. These levels have remained stable over time, although limited data are available from major high burden settings. In addition to the emergence of drug resistance due to inadequate treatment, there is growing evidence that direct transmission is a large contributor to the RR/MDR-TB epidemic. Only 340,000 of the estimated 580,000 incident cases of RR/MDR-TB were notified to WHO in 2015. Among these, only 125,000 were initiated on second-line treatment. RR/MDR-TB epidemics are likely to be driven by direct transmission. The most important risk factor for MDR-TB is a history of previous treatment. Other risk factors vary according to setting but can include hospitalisation, incarceration and HIV infection. Children have the same risk of MDR-TB as adults and represent a diagnostic and treatment challenge. Rapid molecular technologies have revolutionized the diagnosis of drug-resistant TB. Until capacity can be established to test every TB patient for rifampicin resistance, countries should focus on gradually expanding their coverage of testing. DNA sequencing technologies are being increasingly incorporated into patient management and drug resistance surveillance. They offer additional benefits over conventional culture-based phenotypic testing, including a faster turn-around time for results, assessment of resistance patterns to a range of drugs, and investigation of strain clustering and transmission.

Entities:  

Keywords:  Antimicrobial Resistance; Diagnostics; Epidemiology; Surveillance; Transmission

Mesh:

Substances:

Year:  2017        PMID: 29116637     DOI: 10.1007/978-3-319-64371-7_11

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  7 in total

1.  Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques.

Authors:  Michel P M Vierboom; Agnes L Chenine; Patricia A Darrah; Richard A W Vervenne; Charelle Boot; Sam O Hofman; Claudia C Sombroek; Karin Dijkman; Mohamed A Khayum; Marieke A Stammes; Krista G Haanstra; Chantal Hoffmann; Doris Schmitt; Nathalie Silvestre; Alexander G White; H Jacob Borish; Robert A Seder; Nadia Ouaked; Stephane Leung-Theung-Long; Geneviève Inchauspé; Ravi Anantha; Mary Limbach; Thomas G Evans; Danilo Casimiro; Maria Lempicki; Dominick J Laddy; Aurelio Bonavia; Frank A W Verreck
Journal:  NPJ Vaccines       Date:  2020-05-14       Impact factor: 7.344

Review 2.  Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century.

Authors:  Jean Claude S Ngabonziza; Leen Rigouts; Gabriela Torrea; Tom Decroo; Eliane Kamanzi; Pauline Lempens; Aniceth Rucogoza; Yves M Habimana; Lies Laenen; Belamo E Niyigena; Cécile Uwizeye; Bertin Ushizimpumu; Wim Mulders; Emil Ivan; Oren Tzfadia; Claude Mambo Muvunyi; Patrick Migambi; Emmanuel Andre; Jean Baptiste Mazarati; Dissou Affolabi; Alaine N Umubyeyi; Sabin Nsanzimana; Françoise Portaels; Michel Gasana; Bouke C de Jong; Conor J Meehan
Journal:  J Clin Tuberc Other Mycobact Dis       Date:  2022-01-24

3.  Assessing whether isoniazid is essential during the first 14 days of tuberculosis therapy: a phase 2a, open-label, randomised controlled trial.

Authors:  Andreas Diacon; Sachiko Miyahara; Rodney Dawson; Xin Sun; Evelyn Hogg; Kathleen Donahue; Michael Urbanowski; Veronique De Jager; Courtney V Fletcher; Richard Hafner; Susan Swindells; William Bishai
Journal:  Lancet Microbe       Date:  2020-06-08

4.  Evaluation of heterologous prime-boost vaccination strategies using chimpanzee adenovirus and modified vaccinia virus for TB subunit vaccination in rhesus macaques.

Authors:  Michel P M Vierboom; Agnes L Chenine; Patricia A Darrah; Richard A W Vervenne; Charelle Boot; Sam O Hofman; Claudia C Sombroek; Karin Dijkman; Mohamed A Khayum; Marieke A Stammes; Krista G Haanstra; Chantal Hoffmann; Doris Schmitt; Nathalie Silvestre; Alexander G White; H Jacob Borish; Robert A Seder; Nadia Ouaked; Stephane Leung-Theung-Long; Geneviève Inchauspé; Ravi Anantha; Mary Limbach; Thomas G Evans; Danilo Casimiro; Maria Lempicki; Dominick J Laddy; Aurelio Bonavia; Frank A W Verreck
Journal:  NPJ Vaccines       Date:  2020-05-14       Impact factor: 7.344

Review 5.  Of tuberculosis and non-tuberculous mycobacterial infections - a comparative analysis of epidemiology, diagnosis and treatment.

Authors:  Radha Gopalaswamy; Sivakumar Shanmugam; Rajesh Mondal; Selvakumar Subbian
Journal:  J Biomed Sci       Date:  2020-06-17       Impact factor: 8.410

6.  Epidemiology of drug-resistant tuberculosis in Chongqing, China: A retrospective observational study from 2010 to 2017.

Authors:  Bo Wu; Ya Yu; Changting Du; Ying Liu; Daiyu Hu
Journal:  PLoS One       Date:  2019-12-10       Impact factor: 3.240

7.  Incidence Density and Predictors of Multidrug-Resistant Tuberculosis Among Individuals With Previous Tuberculosis History: A 15-Year Retrospective Cohort Study.

Authors:  Qinglin Cheng; Li Xie; Le Wang; Min Lu; Qingchun Li; Yifei Wu; Yinyan Huang; Qingjun Jia; Gang Zhao
Journal:  Front Public Health       Date:  2021-05-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.